Glenmark Pharmaceuticals Limited
NSE: GLENMARKINE935A01035·HealthcareMidcap 150·www.glenmarkpharma.com ↗·Mcap ₹69,769 Cr·Listed 2000
₹2,380.00▼ ₹50.40  (−2.07%)
52W: ₹1,793 – ₹2,538 · Vol: 7.9L shares · Close 25 Sept
Set Alert

Quarterly results

consolidated · as filed with NSE · Q1 FY27 back to Q4 FY18
₹ croreQ1 FY27Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q3 FY25Q2 FY25Q1 FY25Q4 FY24Q3 FY24Q2 FY24Q1 FY24Q4 FY23Q3 FY23Q2 FY23Q1 FY23Q4 FY22Q3 FY22Q2 FY22Q1 FY22Q4 FY21Q3 FY21Q2 FY21Q1 FY21Q4 FY20Q3 FY20Q2 FY20Q1 FY20Q4 FY19Q3 FY19Q2 FY19Q4 FY18
Revenue from operations4,0183,7713,9016,0473,2643,2563,3883,4343,2443,0632,5073,2073,4023,3743,4643,3752,7773,0193,1733,1472,9652,8602,7872,9522,3452,7672,7362,8152,3232,5632,5552,5812,280
Other income65.818944.520126.411.731.139.431.577345.41.720.9−40.276.497.418310713.9−13.158.68.515.1−31.958.544.13380.81.739.1−10914069.6
Total expenses3,4413,1993,2273,8952,8722,8872,9623,0012,8132,8592,9973,0083,0373,0253,1032,9922,5522,7742,6662,7492,5802,5312,4672,5842,0742,5272,4982,5492,1652,3622,2922,3092,101
EBITDA8057638702,360581561600602588504−209462631605620622432463693590574523530553478466440450342364435440327
EBITDA margin20.0%20.2%22.3%39.0%17.8%17.2%17.7%17.5%18.1%16.5%-8.3%14.4%18.6%17.9%17.9%18.4%15.5%15.3%21.8%18.8%19.3%18.3%19.0%18.7%20.4%16.8%16.1%16.0%14.7%14.2%17.0%17.0%14.3%
Finance costs5442.641.466.558.266.752.348.539.614913412111210997.383.16086.966.768.975.683.395.480.693.798.596.189.89381.988.585.174.4
Depreciation17314815414113012512312011815114714115514716215614713211912311311111510411312610694.290.78183.182.573.5
Profit before tax64338853496795.68456473462531−521−124333−491471480408270343385444338348339358318271347160240154580248
Tax16186.413135748.63.61081181221,769−71.855.9160−87.618020219797.110311013710499.810510497.780.191.850.678.637.716696.8
Net profit483301403610474.4348354340−1,214−331−63.6173−403291279211173240275307234248234254220191256109162116414152
Net margin12.0%8.0%10.3%10.1%1.4%0.1%10.3%10.3%10.5%-39.6%-13.2%-2.0%5.1%-11.9%8.4%8.3%7.6%5.7%7.6%8.7%10.3%8.2%8.9%7.9%10.8%8.0%7.0%9.1%4.7%6.3%4.6%16.0%6.7%
EPS (₹)17.1110.6814.2921.631.660.1612.3312.5512.06-44.04-16.66-7.115.31-15.189.669.236.825.517.860.0010.868.298.808.299.007.816.769.063.875.734.1214.675.37
Net profit YoY+927.9%+6773.2%+15.9%+72.2%−86.2%+100.4%+205.2%+657.8%+96.5%−201.2%−213.8%−122.8%−18.0%−333.6%+21.3%+1.4%−31.1%−26.2%−3.4%+17.4%+20.7%+6.2%+30.0%−8.4%+132.5%+36.3%+64.0%−38.3%–+6.6%–––

Annual results

financial years ending March · from the fourth-quarter filings
₹ croreFY26FY25FY24FY23FY22FY21FY20FY19FY18
Revenue from operations16,98313,32211,81312,99012,30510,94410,6419,8659,103
Other income46111484031716750.216020891.4
Total expenses13,19211,66311,71611,67310,7699,6569,7378,9408,075
EBITDA4,5722,3511,1952,2782,3202,0841,6981,5861,615
EBITDA margin26.9%17.7%10.1%17.5%18.9%19.0%16.0%16.1%17.7%
Finance costs209207516350298353377335286
Depreciation573486582611487444417326302
Profit before tax1,9851,39936.58681,4411,3821,0961,3011,119
Tax6233521,867491448412320376315
Net profit1,3621,047−1,434377994970776925804
Net margin8.0%7.9%-12.1%2.9%8.1%8.9%7.3%9.4%8.8%
EPS (₹)48.2637.11-67.3010.5333.3734.3827.5032.7828.49
Net profit YoY+30.1%+173.0%−479.8%−62.0%+2.4%+25.0%−16.1%+15.1%–
EPS is as filed for each period and is not restated for later bonus issues or splits.

Cash flow

annual · ₹ crore
₹ croreFY26FY25FY24FY23FY22
Operating cash flow3,445−828−2656251,109
Investing cash flow−1,2832.14,369−528−333
Financing cash flow−2,709787−3,906−77.5−520
Capital expenditure1,358750898608790
Free cash flow (CFO − capex)2,087−1,577−1,16417.6319

Net profit trend

annual, ₹ crore
FY21
₹970
FY22
₹994+2%
FY23
₹377−62%
FY24
₹−1,434−480%
FY25
₹1,047+173%
FY26
₹1,362+30%

Result filings

as filed with NSE · PDF and XBRL
PeriodBasisFiledDocuments
Q1 FY27Consolidated31 Jul 2026PDF on NSE XBRL
Q1 FY27Standalone31 Jul 2026PDF on NSE XBRL
Q4 FY26Consolidated · audited29 May 2026PDF on NSE XBRL
Q4 FY26Standalone · audited–PDF on NSE XBRL
Q4 FY26Standalone · audited29 May 2026PDF on NSE XBRL
Q3 FY26Consolidated30 Jan 2026PDF on NSE XBRL
Q3 FY26Standalone30 Jan 2026PDF on NSE XBRL
Q2 FY26Consolidated14 Nov 2025PDF on NSE XBRL
Q2 FY26Standalone14 Nov 2025PDF on NSE XBRL
Q1 FY26Consolidated14 Aug 2025 PDF XBRL

Annual reports

NSE archive
Key ratios
P/E (TTM)5Y avg 40.1×37.4×
P/B5Y avg 3.82×6.39×
ROEFY26, on average equity14.1%
Net margin8.0%
Debt / equity0.00×
Revenue CAGR (3Y)9.3%
Profit CAGR (3Y)53.4%
EPS (TTM)₹63.71
Market cap₹67,164 Cr
Computed from the filings and the last close. Market cap uses the latest share count from the balance sheet.
P/B vs history
6.39×
vs 8-point avg 3.82× (+67%)
1.15× low3.82× avg6.39× high
History points are balance-sheet dates (2022 → 2026), priced at the adjusted close on each date.
Balance sheet 31 Mar 2026
Total assets₹19,908 Cr+24%
Net worth₹10,512 Cr+19%
Total borrowings₹0 Cr−100%
Cash & bank balances₹1,175 Cr−30%
Investments₹42 Cr−25%
Inventories₹3,431 Cr+13%
Trade receivables₹4,963 Cr+49%
Trade payables₹3,744 Cr+45%
Change vs the same date a year earlier.
Shareholding 30 Jun 2026
%Jun 26Mar 26Dec 25Sept 25Jun 25Mar 25Dec 24Sept 24Jun 24Mar 24Dec 23Sept 23
Promoter46.6546.6546.6546.6546.6546.6546.6546.6546.6546.6446.6546.65
FII20.8920.3419.2020.7320.6223.1623.5123.0520.9821.3823.7124.80
DII18.6019.2920.0918.6117.6414.6013.8513.2113.9213.3610.9210.32
of which MF16.7616.8017.8616.3115.55–––––––
Retail10.6010.3210.7710.8111.6812.3212.6513.6014.5814.8314.7814.84
Other public3.263.403.293.203.413.273.343.493.873.793.943.39
2,11,418 shareholders · NSE shareholding pattern filings.